These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11675061)

  • 21. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.
    Tfelt-Hansen PC; Olesen J
    J Headache Pain; 2012 Jun; 13(4):271-5. PubMed ID: 22430431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
    Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
    Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
    Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
    Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.
    Wainscott DB; Krushinski JH; Audia JE; Schaus JM; Zgombick JM; Lucaites VL; Nelson DL
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Mar; 371(3):169-77. PubMed ID: 15900510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Almotriptan: an effective and well-tolerated treatment for migraine pain.
    Pascual J
    Drugs Today (Barc); 2003; 39 Suppl D():31-6. PubMed ID: 15071618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eletriptan for acute migraine.
    Smith LA; Oldman AD; McQuay HJ; Moore RA
    Cochrane Database Syst Rev; 2001; (3):CD003224. PubMed ID: 11687056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis.
    Ramadan NM; Skljarevski V; Phebus LA; Johnson KW
    Cephalalgia; 2003 Oct; 23(8):776-85. PubMed ID: 14510923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?
    Neeb L; Meents J; Reuter U
    Neurotherapeutics; 2010 Apr; 7(2):176-82. PubMed ID: 20430316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine.
    Gijsman H; Kramer MS; Sargent J; Tuchman M; Matzura-Wolfe D; Polis A; Teall J; Block G; Ferrari MD
    Cephalalgia; 1997 Oct; 17(6):647-51. PubMed ID: 9350384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.
    Gomez-Mancilla B; Cutler NR; Leibowitz MT; Spierings EL; Klapper JA; Diamond S; Goldstein J; Smith T; Couch JR; Fleishaker J; Azie N; Blunt DE
    Cephalalgia; 2001 Sep; 21(7):727-32. PubMed ID: 11595000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.
    Dowson AJ; Massiou H; Laínez JM; Cabarrocas X
    Cephalalgia; 2002 Jul; 22(6):453-61. PubMed ID: 12133045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks.
    Olesen J
    Cephalalgia; 2010 Oct; 30(10):1157-8. PubMed ID: 20855360
    [No Abstract]   [Full Text] [Related]  

  • 33. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group.
    Mathew NT; Asgharnejad M; Peykamian M; Laurenza A
    Neurology; 1997 Dec; 49(6):1485-90. PubMed ID: 9409334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain.
    Lucaites VL; Krushinski JH; Schaus JM; Audia JE; Nelson DL
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Mar; 371(3):178-84. PubMed ID: 15900511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zolmitriptan: a review of its use in migraine.
    Spencer CM; Gunasekara NS; Hills C
    Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study.
    Pascual J; Falk RM; Piessens F; Prusinski A; Docekal P; Robert M; Ferrer P; Luria X; Segarra R; Zayas JM
    Cephalalgia; 2000 Jul; 20(6):588-96. PubMed ID: 11075844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
    Tuchman M; Hee A; Emeribe U; Silberstein S
    CNS Drugs; 2006; 20(12):1019-26. PubMed ID: 17140280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.
    Garcia-Ramos G; MacGregor EA; Hilliard B; Bordini CA; Leston J; Hettiarachchi J
    Cephalalgia; 2003 Nov; 23(9):869-76. PubMed ID: 14616928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
    Ashcroft DM; Millson D
    Pharmacoepidemiol Drug Saf; 2004 Feb; 13(2):73-82. PubMed ID: 14998068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety of triptans in the treatment of patients with migraine.
    Jamieson DG
    Am J Med; 2002 Feb; 112(2):135-40. PubMed ID: 11835952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.